300439 美康生物
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,406,710-4.35%1,885,8692,489,0862,251,5322,302,032
减:营业总成本1,191,514-6.19%1,661,4372,206,5562,012,5462,117,682
    其中:营业成本762,448-5.94%1,044,6881,539,4701,340,2241,453,738
               财务费用(6,464)68.52%(1,719)4,82926,09053,455
               资产减值损失(1,602)182.53%(21,271)(34,694)(24,472)(63,551)
公允价值变动收益380----165698--
投资收益14,47538.43%14,9273,712(3,424)17,051
    其中:对联营企业和合营企业的投资收益8,836-32.68%16,315(12,216)10,12818,611
营业利润250,213-3.64%279,117228,641219,702172,919
利润总额254,980-3.31%295,679223,306218,236347,049
减:所得税费用31,651-21.01%36,17918,10228,08453,480
净利润223,330-0.14%259,500205,204190,153293,568
减:非控股权益(1,034)-83.62%2,9496,67710,665(5,912)
股东净利润224,364-2.43%256,551198,527179,488299,481

市场价值指针
每股收益 (元) *0.584-2.66%0.6700.5200.4800.870
每股派息 (元) *----0.1340.1050.0950.157
每股净资产 (元) *7.5246.79%7.0896.5546.1284.786
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容